Athira appoints Grant Pickering director; CEO gets $543k salary, 50% bonus target, enhanced severance

LeonaBio, Inc.

Grant Pickering (CEO of Vaxcyte) appointed to board effective Jan 27, 2022.
CEO Mark Litton salary raised from $510k to $543,400; bonus target increased from 40% to 50%.
Amended severance: 12 months base salary (non-CIC) or 18 months salary + 150% bonus (CIC), plus equity acceleration.
Director compensation policy amended: $35k/year cash retainer; initial option grant 27,742 shares vesting monthly over 3 years; annual option grant 13,871 shares.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Grant Pickering

Director

LONA · LeonaBio, Inc.

Effective: 2022-01-27
Filed: January 31, 2022, 6:59 PM ET

On January 27, 2022, the board of directors of Athira Pharma, Inc. (the “Company” or “Athira”), upon recommendation from the nominating and corporate governance committee of the Company’s board of directors (the “Board”), appointed Grant Pickering as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Grant Pickering was appointed as Director at LeonaBio, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 27, 2022, the board of directors of Athira Pharma, Inc. (the “Company” or “Athira”), upon recommendation from the nominating and corporate governance committee of the Company’s board of directors (the “Board”), appointed Grant Pickering as a director of the Company, effective immediately.

View on SEC.gov

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-023358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.